Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the total market value of drugs to treat coronary heart disease (CHD) could reach $15 billion in 2007 and $23 billion in 2012. Newer, more expensive statins like AstraZeneca's Crestor will help drive this growth. The new Pharmacor study entitled Coronary Heart Disease also finds that the number of total prevalent cases of CHD will increase from 187 million in 2002 to 217 million in 2012.

"Less potent statins, such as Bristol-Myers Squibb's Pravachol, Sankyo's Mevalotin, Merck & Co.'s Mevacor, Novartis's Lescol, and generics, will be replaced with more-expensive and more-potent statins like Crestor," said Nicola Maidwell, Ph.D., analyst at Decision Resources. "Another potent statin, Warner-Lambert/Pfizer's Lipitor, will enjoy higher uptake after disclosure of randomized clinical trial data including mortality and morbidity end points that verify the usefulness of the drug in CHD, and increased emphasis by physicians on "lower is better" lipid treatment goals. Ongoing clinical trials that will likely increase statin treatment rates include the Aggressive Lipid- Lowering Initiation Abates New Cardiac Events (ALLIANCE) and the Incremental Decrease in End Points Through Aggressive Lipid-Lowering (IDEAL) trials."

Disease Facts-Coronary Heart Disease

CHD, which occurs when atherosclerotic plaque deposits partly occlude coronary vessels, is a leading cause of death in the major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). The disease burden from this indication is immense: the American Heart Association estimates that CHD costs the Medicare system more than $10 billion each year.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Coronary Heart Disease is a Cardium study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

AstraZeneca's Exanta Will Surpass $2.4 Billion in Sales in 2012, According to a New Study From Decision Resources

View Now